• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

三阴性乳腺癌的最新治疗进展。

Recent treatment progress of triple negative breast cancer.

机构信息

Institute for Special Environmental Biophysics, Key Laboratory for Space Bioscience and Biotechnology, School of Life Sciences, Northwestern Polytechnical University, Xi'an, 710072, Shaanxi, PR China.

The First Hospital of Jilin University, Changchun, Jilin Province, 130021, PR China.

出版信息

Prog Biophys Mol Biol. 2020 Mar;151:40-53. doi: 10.1016/j.pbiomolbio.2019.11.007. Epub 2019 Nov 21.

DOI:10.1016/j.pbiomolbio.2019.11.007
PMID:31761352
Abstract

Breast cancer (BC) is a serious worldwide disease that threatens women's health. Particularly, the morbidity of triple-negative breast cancer (TNBC) is higher than that of other BC types due to its high molecular heterogeneity, metastatic potential and poor prognosis. TNBC lacks of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), so there are still no effective treatment methods for TNBC. Here, we reviewed the classification of TNBC, its molecular mechanisms of pathogenesis, treatment methods and prognosis. Finding effective targets is critical for the treatment of TNBC. Also, refining the classification of TNBC is benefited to choose the treatment of TNBC, because the sensitivity of chemotherapy is different in different TNBC. Some new treatment methods have been proposed in recent years, such as nutritional therapy and noncoding RNA treatment methods. There are some disadvantages, such as the side effect on normal cells after nutrient deprivation, low specificity and instability of noncoding RNA. More studies are necessary to improve the treatment of TNBC.

摘要

乳腺癌(BC)是一种严重的全球性疾病,威胁着妇女的健康。特别是三阴性乳腺癌(TNBC)的发病率高于其他 BC 类型,因为它具有较高的分子异质性、转移潜能和不良预后。TNBC 缺乏雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体 2(HER2),因此目前仍然没有有效的 TNBC 治疗方法。在这里,我们回顾了 TNBC 的分类、发病机制的分子机制、治疗方法和预后。寻找有效的靶点对于治疗 TNBC 至关重要。此外,细化 TNBC 的分类有助于选择 TNBC 的治疗方法,因为不同的 TNBC 对化疗的敏感性不同。近年来提出了一些新的治疗方法,如营养治疗和非编码 RNA 治疗方法。这些方法存在一些缺点,如营养剥夺后对正常细胞的副作用、非编码 RNA 的特异性和稳定性低。需要进一步研究以改善 TNBC 的治疗。

相似文献

1
Recent treatment progress of triple negative breast cancer.三阴性乳腺癌的最新治疗进展。
Prog Biophys Mol Biol. 2020 Mar;151:40-53. doi: 10.1016/j.pbiomolbio.2019.11.007. Epub 2019 Nov 21.
2
Immunological therapy: A novel thriving area for triple-negative breast cancer treatment.免疫疗法:三阴性乳腺癌治疗的新兴领域。
Cancer Lett. 2019 Feb 1;442:409-428. doi: 10.1016/j.canlet.2018.10.042. Epub 2018 Nov 9.
3
Triple negative breast cancer: looking for the missing link between biology and treatments.三阴性乳腺癌:探寻生物学与治疗之间缺失的环节
Oncotarget. 2015 Sep 29;6(29):26560-74. doi: 10.18632/oncotarget.5306.
4
PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis.蛋白激酶Cλ/ι信号传导促进三阴性乳腺癌的生长和转移。
Cell Death Differ. 2014 Sep;21(9):1469-81. doi: 10.1038/cdd.2014.62. Epub 2014 May 2.
5
Triple-negative breast cancer molecular subtyping and treatment progress.三阴性乳腺癌分子分型及治疗进展。
Breast Cancer Res. 2020 Jun 9;22(1):61. doi: 10.1186/s13058-020-01296-5.
6
Recent Progress in Triple Negative Breast Cancer Research.三阴性乳腺癌研究的最新进展
Asian Pac J Cancer Prev. 2016;17(4):1595-608. doi: 10.7314/apjcp.2016.17.4.1595.
7
MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.微小RNA 603作为一种肿瘤抑制因子,通过靶向延伸因子2激酶来抑制三阴性乳腺癌的肿瘤发生。
Oncotarget. 2017 Feb 14;8(7):11641-11658. doi: 10.18632/oncotarget.14264.
8
Serum Human Epidermal Growth Factor 2 is a Novel Biomarker for Recurrence and Metastasis in Triple Negative Breast Cancer.血清人表皮生长因子2是三阴性乳腺癌复发和转移的一种新型生物标志物。
Clin Lab. 2017 Jan 1;63(1):53-58. doi: 10.7754/Clin.Lab.2016.160524.
9
Comprehensive analysis of novel three-long noncoding RNA signatures as a diagnostic and prognostic biomarkers of human triple-negative breast cancer.全面分析新型三长非编码 RNA 标志物作为人类三阴性乳腺癌的诊断和预后生物标志物。
J Cell Biochem. 2019 Mar;120(3):3185-3196. doi: 10.1002/jcb.27584. Epub 2018 Sep 11.
10
Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer.三阴性乳腺癌化疗耐药的分子靶点及治疗策略。
Med Oncol. 2021 Nov 23;39(1):14. doi: 10.1007/s12032-021-01610-x.

引用本文的文献

1
Development of an All-Hydrocarbon Stapled Peptide Targeting BRK1 in Triple-Negative Breast Cancer.一种靶向三阴性乳腺癌中BRK1的全烃化稳定肽的研发。
ACS Med Chem Lett. 2025 Jul 28;16(8):1585-1591. doi: 10.1021/acsmedchemlett.5c00221. eCollection 2025 Aug 14.
2
Molecular docking and dynamics studies to identify novel active compounds targeting potential breast cancer receptor proteins from an indigenous herb Linn.分子对接和动力学研究,以从一种本土草药Linn.中鉴定靶向潜在乳腺癌受体蛋白的新型活性化合物。
F1000Res. 2024 Dec 9;13:385. doi: 10.12688/f1000research.146862.3. eCollection 2024.
3
Homologous targeted neutrophils-liposome system for pyroptosis-enhanced antitumor immunotherapy of triple-negative breast cancer.
用于焦亡增强三阴性乳腺癌抗肿瘤免疫治疗的同源靶向中性粒细胞-脂质体系统
Mater Today Bio. 2025 May 24;32:101904. doi: 10.1016/j.mtbio.2025.101904. eCollection 2025 Jun.
4
Anticancer potential of exosome-like nanoparticles isolated from in breast cancer.从乳腺癌中分离出的类外泌体纳米颗粒的抗癌潜力。
3 Biotech. 2025 Jun;15(6):186. doi: 10.1007/s13205-025-04349-8. Epub 2025 May 24.
5
A Preliminary Study on the Therapeutic Role of γδT Cells in Triple-Negative Breast Cancer.γδT细胞在三阴性乳腺癌治疗作用中的初步研究
Kaohsiung J Med Sci. 2025 Aug;41(8):e70029. doi: 10.1002/kjm2.70029. Epub 2025 Apr 28.
6
Oncogenic properties of wild-type DNA repair gene FANCA in breast cancer.野生型DNA修复基因FANCA在乳腺癌中的致癌特性。
Cell Rep. 2025 Apr 22;44(4):115480. doi: 10.1016/j.celrep.2025.115480. Epub 2025 Mar 26.
7
enhances the proliferation, migration, and invasion of triple-negative breast cancer cells via the regulation of the TGF-β signaling pathway.通过调节转化生长因子-β(TGF-β)信号通路增强三阴性乳腺癌细胞的增殖、迁移和侵袭能力。
Transl Cancer Res. 2025 Feb 28;14(2):1141-1156. doi: 10.21037/tcr-24-1374. Epub 2025 Feb 26.
8
Cellular Epigenetic Targets and Epidrugs in Breast Cancer Therapy: Mechanisms, Challenges, and Future Perspectives.乳腺癌治疗中的细胞表观遗传靶点与表观遗传药物:作用机制、挑战及未来展望
Pharmaceuticals (Basel). 2025 Feb 3;18(2):207. doi: 10.3390/ph18020207.
9
Integration of CRISPR/dCas9-Based methylation editing with guide positioning sequencing identifies dynamic changes of mrDEGs in breast cancer progression.基于CRISPR/dCas9的甲基化编辑与引导定位测序相结合,可识别乳腺癌进展过程中mrDEG的动态变化。
Cell Mol Life Sci. 2025 Jan 21;82(1):46. doi: 10.1007/s00018-024-05562-z.
10
Threonine and tyrosine kinase (TTK) mRNA and protein expression in breast cancer; prognostic significance in the neoadjuvant setting.苏氨酸和酪氨酸激酶(TTK)在乳腺癌中的mRNA和蛋白质表达;新辅助治疗环境中的预后意义。
Histopathology. 2025 May;86(6):916-932. doi: 10.1111/his.15399. Epub 2025 Jan 7.